CN112752761B - 双环杂芳族环衍生物 - Google Patents

双环杂芳族环衍生物 Download PDF

Info

Publication number
CN112752761B
CN112752761B CN201980054331.4A CN201980054331A CN112752761B CN 112752761 B CN112752761 B CN 112752761B CN 201980054331 A CN201980054331 A CN 201980054331A CN 112752761 B CN112752761 B CN 112752761B
Authority
CN
China
Prior art keywords
alkyl
compound
general formula
mixture
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
CN201980054331.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112752761A (zh
Inventor
杵渊政彦
近藤丈和
落合贡司
西谷洋辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinglin Pharmaceutical Holdings Co ltd
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Priority to CN202410202422.0A priority Critical patent/CN118084937A/zh
Publication of CN112752761A publication Critical patent/CN112752761A/zh
Application granted granted Critical
Publication of CN112752761B publication Critical patent/CN112752761B/zh
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980054331.4A 2018-08-21 2019-08-20 双环杂芳族环衍生物 Withdrawn - After Issue CN112752761B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410202422.0A CN118084937A (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-154411 2018-08-21
JP2018154411 2018-08-21
PCT/JP2019/032335 WO2020040104A1 (ja) 2018-08-21 2019-08-20 ２環性ヘテロ芳香環誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410202422.0A Division CN118084937A (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物

Publications (2)

Publication Number Publication Date
CN112752761A CN112752761A (zh) 2021-05-04
CN112752761B true CN112752761B (zh) 2024-03-29

Family

ID=69593150

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980054331.4A Withdrawn - After Issue CN112752761B (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物
CN202410202422.0A Withdrawn CN118084937A (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410202422.0A Withdrawn CN118084937A (zh) 2018-08-21 2019-08-20 双环杂芳族环衍生物

Country Status (19)

Country Link
US (1) US11952387B2 (https=)
EP (1) EP3842439A4 (https=)
JP (1) JP7309725B2 (https=)
KR (1) KR20210046649A (https=)
CN (2) CN112752761B (https=)
AU (1) AU2019324089B2 (https=)
BR (1) BR112021002515A2 (https=)
CA (1) CA3104054A1 (https=)
CL (1) CL2020003116A1 (https=)
CO (1) CO2021000512A2 (https=)
IL (1) IL278885A (https=)
MX (1) MX2020013039A (https=)
MY (1) MY200452A (https=)
PH (1) PH12020551991A1 (https=)
SA (1) SA520420914B1 (https=)
SG (1) SG11202012616RA (https=)
TW (1) TWI811428B (https=)
WO (1) WO2020040104A1 (https=)
ZA (1) ZA202101146B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231436A1 (en) * 2023-05-11 2024-11-14 Arxada Ag Hydrogenation of cyclic ketones

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0649066A (ja) * 1992-04-15 1994-02-22 Sterling Winthrop Inc １，２，４−オキサジアゾリルフェノキシアルキルイソオキサゾール類及び抗ウイルス薬としてのそれらの用途
JPH07503966A (ja) * 1992-02-25 1995-04-27 ローン−プーラン・ロレ・ソシエテ・アノニム ピリジルピロロチアゾールカルボキシアミド誘導体の新規な治療的適用
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
CN1148339A (zh) * 1994-05-13 1997-04-23 圣诺菲温特洛普公司 噻二唑类以及它们作为抗细小核糖核酸病毒剂的应用
JPH11106340A (ja) * 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
WO2000057878A1 (en) * 1999-03-31 2000-10-05 The Procter & Gamble Company Thiadiazolyl urea or thiourea derivatives for antiviral treatment
CN1849323A (zh) * 2003-09-09 2006-10-18 P·安杰莱蒂分子生物学研究所 作为抗病毒药的噻吩并吡咯
WO2010012345A1 (en) * 2008-07-29 2010-02-04 Merck Patent Gmbh Imidazothiadiazoles derivatives
CN101878219A (zh) * 2007-09-27 2010-11-03 西班牙国家癌症研究中心 用于作为蛋白激酶抑制剂使用的咪唑并噻二唑类
CN102388055A (zh) * 2009-04-02 2012-03-21 西班牙国家癌症研究中心 咪唑并[2,1-b][1,3,4]噻二唑衍生物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT65486B (en) 1975-08-28 1978-03-24 Lilly Co Eli Process for the preparation of carbonil-substituted 1-sulfonylbenzimidazoles
JPH0649066B2 (ja) * 1985-02-14 1994-06-29 積水化学工業株式会社 医療用粘着シ−トもしくはテ−プ
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7229480B2 (en) 2004-02-13 2007-06-12 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP2016075A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
CA2735875A1 (en) * 2008-09-03 2010-03-11 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
ES2665277T3 (es) 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
US9309236B2 (en) 2011-10-05 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University PI-kinase inhibitors with broad spectrum anti-infective activity
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
WO2014078813A1 (en) 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
SG11201504291SA (en) 2012-12-20 2015-07-30 Ucb Biopharma Sprl Therapeutically active pyrazolo-pyrimidine derivatives
EP3004060B1 (en) 2013-05-30 2019-11-27 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
RU2689788C2 (ru) 2014-01-22 2019-05-29 Куровир Аб ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ
JP6678599B2 (ja) 2014-06-13 2020-04-08 ユニバーシティー オブ ロチェスター 小分子排出ポンプ阻害剤
GB201410816D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
CN107949563B (zh) 2015-06-24 2020-06-05 库洛维公司 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
WO2017053192A1 (en) 2015-09-21 2017-03-30 The Board Of Regents Of The University Of Texas System Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517264D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
WO2017147526A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20190358196A1 (en) 2016-07-27 2019-11-28 Henry C. Lowe Pi 4-kinase inhibitor as a therapeutic for viral hepatitis, cancer, malaria. autoimmune disorders and inflammation, and a radiosensitizer and immunosuppressant

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503966A (ja) * 1992-02-25 1995-04-27 ローン−プーラン・ロレ・ソシエテ・アノニム ピリジルピロロチアゾールカルボキシアミド誘導体の新規な治療的適用
JPH0649066A (ja) * 1992-04-15 1994-02-22 Sterling Winthrop Inc １，２，４−オキサジアゾリルフェノキシアルキルイソオキサゾール類及び抗ウイルス薬としてのそれらの用途
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
CN1148339A (zh) * 1994-05-13 1997-04-23 圣诺菲温特洛普公司 噻二唑类以及它们作为抗细小核糖核酸病毒剂的应用
JPH11106340A (ja) * 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
WO2000057878A1 (en) * 1999-03-31 2000-10-05 The Procter & Gamble Company Thiadiazolyl urea or thiourea derivatives for antiviral treatment
CN1849323A (zh) * 2003-09-09 2006-10-18 P·安杰莱蒂分子生物学研究所 作为抗病毒药的噻吩并吡咯
CN101878219A (zh) * 2007-09-27 2010-11-03 西班牙国家癌症研究中心 用于作为蛋白激酶抑制剂使用的咪唑并噻二唑类
WO2010012345A1 (en) * 2008-07-29 2010-02-04 Merck Patent Gmbh Imidazothiadiazoles derivatives
CN102388055A (zh) * 2009-04-02 2012-03-21 西班牙国家癌症研究中心 咪唑并[2,1-b][1,3,4]噻二唑衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification of a Series of Compounds with Potent Antiviral Activity for the Treatment of Enterovirus Infections;MacLeod, Angus M.，等;ACS Medicinal Chemistry Letters;第4卷(第4期);585–589 *

Also Published As

Publication number Publication date
WO2020040104A1 (ja) 2020-02-27
TWI811428B (zh) 2023-08-11
JPWO2020040104A1 (ja) 2021-08-12
EP3842439A4 (en) 2022-04-27
CN118084937A (zh) 2024-05-28
ZA202101146B (en) 2022-07-27
AU2019324089B2 (en) 2024-06-13
BR112021002515A2 (pt) 2021-07-27
KR20210046649A (ko) 2021-04-28
US20220332730A1 (en) 2022-10-20
AU2019324089A1 (en) 2020-12-10
CL2020003116A1 (es) 2021-04-16
SG11202012616RA (en) 2021-02-25
US11952387B2 (en) 2024-04-09
CN112752761A (zh) 2021-05-04
CO2021000512A2 (es) 2021-01-29
JP7309725B2 (ja) 2023-07-18
MY200452A (en) 2023-12-27
IL278885A (en) 2021-01-31
CA3104054A1 (en) 2020-02-27
MX2020013039A (es) 2021-02-26
SA520420914B1 (ar) 2023-12-25
TW202021971A (zh) 2020-06-16
PH12020551991A1 (en) 2021-08-02
EP3842439A1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
TW200800182A (en) Nitrogen-containing heterocyclic derivatives substituted by ring-type groups
EP3464278B1 (en) Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
CN105524046B (zh) 制备吡咯化合物的方法
JP5015016B2 (ja) １０ａ−アザライド化合物
TW201136919A (en) Inhibitors of hepatitis C virus NS5B polymerase
WO2016203112A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
JP2022046542A (ja) 細胞毒性ベンゾジアゼピン誘導体の調製方法
AU2002357885A1 (en) Compounds for the treatment of inflammatory disorders
KR20170012413A (ko) 신규한 피롤리딘 화합물 및 멜라노코르틴 수용체 아고니스트로서의 용도
AU2006216289A1 (en) 1-(2H)-isoquinolone derivative
CZ47393A3 (en) Inodole and indazole derivatives, their preparation and use
JP2026062914A (ja) Ｇ９ａ阻害剤
CN112752761B (zh) 双环杂芳族环衍生物
EP1940823A2 (fr) Dérivés de la 1-amino-phtalazine substituee, leur préparation et leur application en thérapeutique
WO1995026953A1 (en) Benzoic acid compound and use thereof as medicine
CN1935779A (zh) N－(n－苯甲酰基－苯丙氨酰基)－苯丙氨酸二肽衍生物及其制备方法和用途
RU2798838C2 (ru) Бициклическое гетероароматическое кольцевое производное
HK40051492A (en) Bicyclic heteroaromatic ring derivative
CN107709318B (zh) 食欲素受体拮抗剂受体化合物的制备方法及其中间体和晶型
CN102924454A (zh) 恩替卡韦的合成方法
TW202402761A (zh) 製備shp2抑制劑的方法
CN104418707B (zh) 一种天然产物补骨脂酚及其对映体的不对称合成方法
JP2023500214A (ja) ３－（｛５－クロロ－１－［３－（メチルスルホニル）プロピル］－１Ｈ－インドール－２イル｝メチル）－１－（２，２，２－トリフルオロエチル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］ピリジン－２－オンの合成
CN111094270A (zh) 光学活性吡咯烷化合物及其制造方法
CN119285569A (zh) 一类五元氮杂环类衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051492

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 3-7 Otemachi 1-chome, Chiyoda ku, Tokyo, Japan

Patentee after: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region after: Japan

Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Patentee before: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region before: Japan

TR01 Transfer of patent right

Effective date of registration: 20241025

Address after: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Patentee after: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region after: Japan

Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Patentee before: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region before: Japan

TR01 Transfer of patent right
AV01 Patent right actively abandoned
AV01 Patent right actively abandoned
AV01 Patent right actively abandoned

Granted publication date: 20240329

Effective date of abandoning: 20251202

AV01 Patent right actively abandoned

Granted publication date: 20240329

Effective date of abandoning: 20251202